Three EU Tecfidera Generics Recommended As Biogen Battles For Exclusivity
Mylan, Polpharma And Neuraxpharm Backed Amid Regulatory Tussle
Following a years-long back-and-forth to establish exclusivity protection for its Tecfidera multiple-sclerosis treatment in Europe, Biogen has ultimately seen the CHMP recommend three generic versions to receive pan-European marketing authorization.
You may also be interested in...
Biogen Will Assert New Tecfidera Patent Amid Hexal Germany Launch
Biogen has conceded that generics to its Tecfidera treatment for relapsing remitting multiple sclerosis may launch “at risk” in the EU, after the US-based player was recently granted further patent protection until 2028.
Neuraxpharm Boosts Branded Business With Established Sanofi Portfolios
CNS specialist Neuraxpharm has purchased two of Sanofi’s product portfolios, substantially expanding the number of branded products it has to offer.
Neuraxpharm’s Brain Acquisition Stems From Expansion Ambitions
Privately-owned Neuraxpharm has found another company to give it further access to a new European market, picking up Athens-based Brain Therapeutics. It aims now to introduce its Buccolam (midazolam) in Greece.